Source BioScience announced it has completed the acquisition of Cambridge Clinical Laboratories (CCL).
The acquisition bolsters the Company’s clinical diagnostics portfolio by leveraging the expertise of the CCL team and new state-of-the-art clinical lab facilities at Vision Park in Cambridge, providing streamlined testing services for both preclinical and clinical research.
CCL provides personalized healthcare diagnostic services spanning oncology, virology, men’s health, gastro and fertility, as well as validation studies for clinical research, to both the NHS and private customers worldwide. The acquisition will complement Source BioScience’s established capabilities in genomics and multiomics, and expand its existing clinical offering, which includes molecular diagnostics, digital pathology and clinical trial support, to provide a complete laboratory service portfolio. By offering comprehensive, end-to-end testing solutions, researchers can confidently progress candidates through R&D, to preclinical and clinical stages with one specialist outsourcing partner - minimizing resource requirements and data bias across the entire development process, with the option for additional support in clinical research and diagnostics.
All staff and assets from CCL will be transferred to the new clinical facilities at the existing Source Genomics site at Vision Park. The facilities will provide a significantly larger laboratory footprint, enabling the Company to expand the capacity of existing services and explore new capabilities for future projects. In addition, the site will increase opportunities for collaboration between the genomics and clinical services teams, providing customers deeper insights into their data.
